Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next
Edgewise Therapeutics shares fell 4.7% to around $26.00 Friday after a clinical update on its EDG-7500 program in hypertrophic cardiomyopathy. The company reported no significant safety concerns in interim Phase 2 data, with over 40 participants enrolled and no clinically meaningful drops in ejection fraction. Biotech stocks lagged, with XBI down 1.16% and IBB off 0.86%, while broader indexes traded flat.